Earlybird leads biotech round

A Dutch biotech company that specializes in non-invasive cardiovascular monitoring has raised €6m in a series B round.

Led by new investor, the German venture firm Earlybird, Amsterdam-based BMEYE has also received investment from Franco-Italian VC, 360 Capital Partners, with existing BMEYE shareholders LSP (Life Sciences Partners) and Techfund returning.

The company was founded in 2005 and in 2006 closed its series A round with LSP as the lead investor.

“Over the past 3 years, BMEYE has developed from an R&D based group to a fully commercial, professional organization” says Rene Kuijten, LSP’s board member. “With the addition of two qualified investors and €6m in new equity funding, the company is well equipped to continue its growth path.”

BMEYE’s main product is Nexfin™, an FDA and CE approved cardiovascular monitor which uses a finger sensor to produce accurate beat-to-beat, non-invasive blood pressure and cardiac output data displayed on an intuitive touch screen.